
NCPA: Any pharma tariffs should be tailored to avoid increasing shortages and costs
NCPA is urging the Trump administration to establish certain exclusions from any tariffs, incentivize U.S. manufacturing through supportive domestic and trade policies, and reform the PBM payment model to strengthen domestic supply chains and reimburse pharmacies fairly.